Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)

Phase 3

Completed

• Conditions: Hepatitis D, Chronic; Hepatitis B, Chronic
• Interventions: Biological: Peginterferon alfa-2b (PegIntron, SCH 54031)

• Registration Number: NCT00686790
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The objective of this study is to determine the effectiveness of peginterferon alfa-2b 1.5 mcg/kg/week administered for 52 weeks (wk) in previously untreated participants coinfected with hepatitis virus B and D. After 52-week treatment and 52-week follow-up, the virologic, biochemical, and histological response will be evaluated.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-12
• Study First Submitted: 2008-05-27
• Study First Submitted QC: 2008-05-29
• Study First Posted: 2008-05-30
• Primary Completion: 2009-05
• Study Completion: 2009-05
• Results First Submitted: 2010-12-21
• Results First Submitted QC: 2010-12-21
• Results First Posted: 2011-01-17
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-08
• Last Update Posted: 2017-04-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

• Participants must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
• Age 18-65 years old.
• HBsAg positive >6 months.
• ALT >= 2 ULN >6 months.
• HDV RNA positive serology.
• Serum antibody to hepatitis delta antigen of IgG and IgM class.
• Knodell score HAI >= 6 and F >= 0; positive test for intrahepatic Delta antigen in liver biopsy.
• Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
• Participants must be free of any clinically significant disease (other than chronic hepatitis B and D), that would interfere with study evaluations.
• Participants must understand and be able to adhere to the dosing and visit schedules, and agree to record symptom severity scores, medication times, concomitant medications, and adverse events accurately and consistently in a daily diary.

Read More

Exclusion Criteria

• Age <18 and >65.
• Concomitant HCV and/or HIV infection.
• Actual liver failure (total serum bilirubin >2.5 x normal, prolonged prothrombin time >3 sec, serum albumin <3 g/dl, history of ascites, variceal bleeding, or hepatic encephalopathy).
• Toxic or autoimmune hepatitis (ANA titers > 1:160), metabolic liver diseases (Wilson disease, hemochromatosis, α-1 antitrypsin deficiency)
• Women who are pregnant or nursing.
• Leukopenia (<2500/mm^3), neutropenia (<1000/mm^3), hemoglobin <10 g/dl, presence of other severe diseases (myocardiopathy, diabetes mellitus, arterial hypertension, neoplasia, neurologic diseases, malnutrition).
• Antiviral, immunomodulatory, corticosteroid, or chemotherapeutical treatment within 6 months of the participation in the study.
• Depression and/or psychiatric disorders.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
PegIntron	Peginterferon alfa-2b (PegIntron, SCH 54031)	All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.

Primary Outcome Measures

Name	Time	Method
Number of Participants With a Biochemical Response	52 weeks (EOT), 104 weeks (EOF)	A participant was defined as a responder if his alanine aminotransferase (ALT) level after 52 weeks, i.e. at EOT, was below the upper reference range as specified by Bioclinica. The normal reference range for ALT is 5-55 U/L.
Number of Participants With a Combined Response	52 weeks (EOT), 104 weeks (EOF)	The combined response was defined as an ALT level below the upper; reference range and a negative HDV-RNA test. The normal reference range for ALT is 5-55 U/L.
Number of Participants With a Virological Response	52 weeks (end of treatment [EOT]), 104 weeks (end of follow-up [EOF]) following treatment initiation	For virological response, a participant was defined as a responder if his/her serum sample tested negative for Hepatitis D Virus - ribonucleic acid (HDV-RNA) by polymerase chain reaction (PCR) at end of treatment (EOT).

Secondary Outcome Measures

Name	Time	Method
Number of Participants With a Liver Histology Response	Baseline and 52 week (EOT)	The liver histology response was defined as at least a 2 point decrease in the necrosis inflammation score (a sum of periportal necrosis \[0-10\], lobular inflammation \[0-4\], portal inflammation \[0-4\], with the total score of 18 representing the worst outcome) and no increase or regression of fibrosis (scored \[0-4\]) in the pre- and post-treatment liver biopsies.; The efficacy of treatment based on histological response was assessed by the investigator as complete response, partial response, minimal response, progressive disease, and not assessable at EOT.
Number of Participants With Hepatitis B Virus (HBV) Replication Response (HBV Response)	52 week (EOT)	Serum samples collected from the participants were tested by PCR to detect HBV-DNA. HBV response was defined as the absence of HBV-deoxyribonucleic acid (HBV-DNA) in serum.